Dr. John Cush RheumNow
5 years 5 months ago
RT from @doctorRBC covering #RNL2021
--------
Make sure to screen your PsO and PsA for depression and mental health. Worsening depression can cause emotional stress, leading to worse disease. #RNL2021
#rheumnow
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Implementing Smoking Cessation Programs #RheumNow
https://t.co/wEBZRd3n8Q https://t.co/c5yfIyl2Vc
Dr. John Cush RheumNow
5 years 5 months ago
#RNL2021 Tweet from @uptoTate
2020 (contact) allergen of the year: Essential Oils! Keep on using 'em in order to put your family-friendly dermatologist's kids through school! Melodie Young, NP #RNL2021
Dr. John Cush RheumNow
5 years 5 months ago
11 RCTs (4,329 pts) & 19 registries (9,739 pts) studied Rx efficacy in CTD pts w/ pulmonary HTN. Overall, Rx (Sildenafil, Treprostinil, Bosentan, etc) reduced mortality 36% vs controls. CTD‐PAH survival was lower (52% v 72%) vs PAH; higher after 2010 https://t.co/IFb3nLiJbL
Dr. John Cush RheumNow
5 years 5 months ago
New podcast available--Mistakes with Steroids
Dr Jack Cush gives his spin on this week's news featured on RheumNow.
Download wherever podcasts are available.
https://t.co/cUI65I9759 https://t.co/fOWJXW50nI
Dr. John Cush RheumNow
5 years 5 months ago
HLA-B27 status does not change the risk of COVID-19 in spondyloarthritis patients. Survey of 3435 SpA pts; shows 76% as HLA-B27 positive. COVID infx was thesame between B27 Pos & Neg pts (1.5% vs 1.4%) and severity was also the same https://t.co/qavodFynr0
Dr. John Cush RheumNow
5 years 5 months ago
Axial Involvement in SpA: A Patient-Centered Exploration
Sponsored by Novartis Medical Affairs
Listen to Ethan Craig, MD, MPH present insights from patient cases to distinguish axial involvement within the spectrum of SpA.
https://t.co/o2q5pTP3WD https://t.co/IXHs0LHSOe
Dr. John Cush RheumNow
5 years 5 months ago
#RNL2021 coverage from @DrPetryna
Refractory RA by Dr. Buch:
-active DZ after >2 b/ts DMARDs
-why rfRA exists:
?Immunologic heterogeneity of RA
?contributing co-morbidities
?unidentified Rx target
-effective Rx in early disease decreases risk of future rfRA" https://t.co/ecrbqlvemf
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Rheumatology Care Derailed by COVID-19
A survey study from the ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.
https://t.co/BqY0vJpdm8 https://t.co/nZcuL4FbEw
Dr. John Cush RheumNow
5 years 5 months ago
Don’t underestimate the utility of Vitamin D for VTE ppx in APS patients. Everyone should get some sun
#RNL2021 Coverage from @doctorRBC #RheumNow
The TOMORROW study assessed the relationship between diet and disease activity in rheumatoid arthritis (RA) patients and has shown that RA patients are more likely to have higher inflammatory diets, but that a change to an anti-inflammatory diet resulted in lower disease activity scores.
Dr. John Cush RheumNow
5 years 5 months ago
Top March Tweet:
The FDA approved tocilizumab for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved)
https://t.co/HXTRPiYEfZ
Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.
Dr. John Cush RheumNow
5 years 5 months ago
#RNL2021 Coverage from @KDAO2011
"Psoriatic Arthritis Pearls by Dr. E Ruderman
-MTX monoRx is effective
-which TNFi does not matter
-Secukinumab 300 mg is better than 150 mg dose
-OK to use IL-17i in pts with FHx of IBD"
#RheumNow
